Market cap
$814 Mln
Revenue (TTM)
$176 Mln
P/E Ratio
--
P/B Ratio
9.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-1,190 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.4
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
46,119,900
10 Years Aggregate
CFO
Kr.-3,377.06 Mln
EBITDA
Kr.-2,349.02 Mln
Net Profit
Kr.-2,607.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zealand Pharma A/S - ADR
| -17.6 | 0.0 | -6.1 | -46.6 | -16.0 | -1.0 | -- |
|
BSE Sensex*
| -10.2 | -0.9 | -7.6 | -7.0 | 7.1 | 8.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|
|
Zealand Pharma A/S - ADR
| -40.6 | 8.3 | 186.0 | -14.6 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Zealand Pharma A/S - ADR
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty... disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Read more
-
Pres & CEO
Mr. Adam Sinding Steensberg M.D.
-
Pres & CEO
Mr. Adam Sinding Steensberg M.D.
-
Headquarters
Copenhagen
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Zealand Pharma A/S - ADR
What is the current share price of Zealand Pharma A/S - ADR Today?
The share price of Zealand Pharma A/S - ADR is $17.59 (NASDAQ) as of 02-Nov-2022 09:30 EDT. Zealand Pharma A/S - ADR has given a return of -15.99% in the last 3 years.
What is the current PB & PE ratio of Zealand Pharma A/S - ADR?
Since, TTM earnings of Zealand Pharma A/S - ADR is negative, P/E ratio is not available.
The P/B ratio of Zealand Pharma A/S - ADR is 9.54 times as on 11-Nov-2022, a 84 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-0.90
|
0.99
|
|
2020
|
-1.61
|
1.16
|
|
2019
|
-1.98
|
0.91
|
|
2018
|
0.62
|
0.32
|
|
2017
|
-1.40
|
0.72
|
What is the 52 Week High and Low of Zealand Pharma A/S - ADR?
The 52-week high and low of Zealand Pharma A/S - ADR are Rs -- and Rs -- as of 26-May-2026.
What is the market cap of Zealand Pharma A/S - ADR?
Zealand Pharma A/S - ADR has a market capitalisation of $ 814 Mln as on 11-Nov-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Zealand Pharma A/S - ADR?
Before investing in Zealand Pharma A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.